Skip to main content

A Clinical Appraisal of Pentapyrrolidinium (M&B 2050) in Hypertensive Patients

 Digital Record
Identifier: 101584929X43

Dates

  • Publication: April 1954

Extent

7 Pages

Creator

Description

Here, Freis's team studied the effectiveness of pentapyrrolidinium (a ganglionic-blocking agent, also called pentolinium) as an antihypertensive treatment. They concluded that the drug had several advantages in the treatment of severe hypertension over another ganglionic-blocking agent, hexamethonium. The drug's attributes, longer duration of action, greater potency, and a more uniform response to oral administration, more than compensated for its side effects and the frequent need to adjust dosage.

Language of Materials

English

Original Profiles System Identifier

XFBBDB

Source Category

Periodical

Freis, Edward D., Edward A. Partenope, Lawrence S. Lilienfield, and John C. Rose. "A Clinical Appraisal of Pentapyrrolidinium (M&B 2050) in Hypertensive Patients." Circulation IX, 4 (April 1954): 540-546. Article. 7 Images.

Circulation

Physical Description

Physical Condition - Good

Creator

Collecting Area Details

Part of the Archives and Modern Manuscripts Collection Collecting Area

Contact:
8600 Rockville Pike
Bldg 38/1E-21, MSC 3819
Bethesda MD 20894 US
1-888-FINDNLM (1-888-346-3656)